ALNYLAM PHARMACEUTICALS INC (ALNY) Stock Balance Sheet
NASDAQ:ALNY - Nasdaq - US02043Q1076 - Common Stock - Currency: USD
| MRQ (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 1.02B | 966.43M | 812.69M | 866.40M | 820.00M | |||
| Marketable Securities | 1.61B | 1.73B | 1.63B | 1.33B | 1.62B | |||
| Receivables | 418.04M | 405.31M | 327.79M | 238.00M | 198.60M | |||
| Inventories | 65.58M | 78.51M | 89.15M | 129.00M | 86.40M | |||
| Other Current Assets | 152.42M | 116.96M | 126.38M | 132.90M | 88.10M | |||
| Total Current Assets | 3.27B | 3.30B | 2.98B | 2.69B | 2.81B | |||
| Non-Current Assets | ||||||||
| PPE Net | 695.92M | 693.93M | 725.79M | 738.60M | 733.60M | |||
| Investments And Advances | N/A | N/A | N/A | N/A | N/A | |||
| Other Non-Current Assets | 249.64M | 250.77M | 121.39M | 115.50M | 101.10M | |||
| Total Non-Current Assets | 945.55M | 944.70M | 847.18M | 854.20M | 834.70M | |||
| TOTAL ASSETS | 4.21B | 4.24B | 3.83B | 3.55B | 3.64B | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 750.18M | 929.36M | 754.52M | 587.40M | 435.70M | |||
| Accounts Payable | 97.40M | 88.42M | 55.52M | 98.10M | 73.40M | |||
| Other Current Liabilities | 228.05M | 168.50M | 157.74M | 82.40M | 186.60M | |||
| Total Current Liabilities | 1.08B | 1.19B | 967.79M | 767.90M | 695.70M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 1.03B | 1.02B | 1.02B | 1.02B | 675.70M | |||
| Other Non-Current Liabilities | 2.00B | 1.96B | 2.06B | 1.92B | 1.68B | |||
| Total Non-Current Liabilities | 3.02B | 2.99B | 3.08B | 2.94B | 2.36B | |||
| TOTAL LIABILITIES | 4.10B | 4.17B | 4.05B | 3.70B | 3.06B | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -7.35B | -7.29B | -7.01B | -6.57B | -5.44B | |||
| Additional Paid In Capital | 7.50B | 7.39B | 6.81B | 6.45B | 6.06B | |||
| Common Shares | 1.30M | 1.29M | 1.26M | 1.20M | 1.20M | |||
| Other Shareholders' Equity | -7.30M | -3.27M | 7.87M | -2.40M | 1.20M | |||
| Shares Outstanding | 130.31M | 129.29M | 125.79M | 123.90M | 120.20M | |||
| Tangible Book Value per Share | 0.89 | 0.52 | -1.75 | -1.28 | 4.89 | |||
| Total Shareholders' Equity | 115.44M | 67.09M | -220.64M | -158.20M | 588.20M | |||
| TOTAL LIABILITIES AND EQUITY | 4.21B | 4.24B | 3.83B | 3.55B | 3.64B | |||
| Statistics | ||||||||
| Debt/Equity | 8.88 | 15.27 | -4.63 | -6.43 | 1.15 | |||
| Current Ratio | 3.04 | 2.78 | 3.08 | 3.51 | 4.04 | |||
| Return On Assets (ROA) | -6.40% | -6.56% | -11.49% | -31.90% | -23.41% | |||
| Return On Equity (ROE) | -233.64% | -414.62% | N/A | N/A | -144.98% | |||
All data in USD , ROIC based on taxRate of 0.21